Trial Profile
A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Soft Tissue Sarcoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 20 Jun 2020
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Alveolar soft part sarcoma; Clear cell sarcoma; Leiomyosarcoma; Malignant fibrous histiocytoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- Acronyms ALTER0203
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 31 May 2020 Results of retrospective analyses evaluating thyroid-stimulating hormone-increased, hypertriglyceridemia and proteinuria as markers of anlotinib efficacy, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Results (n=158) assessing efficacy of anlotinib by age, gender and ECOG performance status, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology